This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Injectable Anthrax vaccine
DynPort Vaccine Company LLC
Drug Names(s): Injectable Anthrax vaccine
Description: The vaccine consists of a highly purified protein, protective antigen.
Deal Structure: In 1997, DVC received a 10-year contract with the U.S. Department of Defense for the development of vaccines against certain acute infectious diseases and contagious diseases, as a result of the 1997 Joint Vaccine Acquisition Program.
In October 2001, AVANT granted DynPort Vaccine Company a license for exclusive rights to use certain components of AVANT's anthrax vaccine technology. Financial terms of the agreement between DVC and AVANT include license fees, milestone payments and royalties.
In January 2003, AVANT was awarded a subcontract by DVC to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. AVANT executed this initial subcontract with DVC and will be reimbursed on a time and materials basis for vaccine development research work performed by AVANT in the amount of $2.5 million.
In September 2007, as a result of AVANT's restructuring after being acquired by Celldex, AVANT is...See full deal structure in Biomedtracker
Injectable Anthrax vaccine News
Additional information available to subscribers only: